Skip to content

Study · Randomized controlled trial · n = 2,074 · 2007

2 results

Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide.

Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R

The Journal of clinical endocrinology and metabolism3 Jul 2007Cited by 37 (Europe PMC)

PMID17609307 (opens in a new tab)DOI10.1210/jc.2006-2439 (opens in a new tab)PepBankPUB-17609307
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    Of seven participants who discontinued study drug because of repeated hypercalciuria, four were in the teriparatide groups and three in the placebo group.

    In plain wordsRepeated high urinary calcium led four people on teriparatide and three on placebo to stop treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedDiscontinuation due to repeated hypercalciuria
    Study

    n = 2,074

    Comparator
    Placebo
    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    20 and 40 microg/d · Up to 12 monthsAs given in this study (human).

    Measurements

    Discontinuations due to repeated hypercalciuria
    4 participants
    teriparatide groups
    Discontinuations due to repeated hypercalciuria
    3 participants
    placebo group
    Discontinuations due to repeated hypercalciuria
    7 participants
    all groups
    Discontinuations due to repeated hypercalciuria
    0.3%
    all participants

    Source sentences

    Summary
    A total of seven participants (0.3%), of which three and four were in the placebo and TPTD groups, respectively, discontinued study drug due to repeated hypercalciuria (>300 mg/d).
    3 context sentences
    Summary · context
    This study included two prospective, randomized, double-blind placebo-controlled clinical trials.
    Summary · context
    A total of 2074 participants with osteoporosis or low bone mass (study 1, 1637 postmenopausal women; study 2, 437 men) were included.
    Summary · context
    Participants were given calcium (1000 mg/d) and vitamin D (400-1200 IU/d) supplements, and were randomized to placebo, TPTD 20 mug/d, or TPTD 40 mug/d.
  2. 02HumanRandomized controlled trialSafety outcome

    In postmenopausal women, teriparatide increased urinary calcium excretion by up to 32 mg/d versus placebo.

    In plain wordsTeriparatide increased urinary calcium compared with placebo in postmenopausal women.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseUrinary calcium excretion
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    20 microg/day · Up to 12 monthsAs given in this study (human).

    Measurements

    Urinary calcium increase
    ≤ 32 mg/d
    versus placebo in study 1

    Source sentences

    Summary
    Post-baseline urinary calcium excretion was increased in the TPTD 20 microg/d group by up to 32 mg/d compared with placebo at the same time point (P < 0.05) in study 1.
    3 context sentences
    Summary · context
    This study included two prospective, randomized, double-blind placebo-controlled clinical trials.
    Summary · context
    A total of 2074 participants with osteoporosis or low bone mass (study 1, 1637 postmenopausal women; study 2, 437 men) were included.
    Summary · context
    Participants were given calcium (1000 mg/d) and vitamin D (400-1200 IU/d) supplements, and were randomized to placebo, TPTD 20 mug/d, or TPTD 40 mug/d.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00853723

Comparison Study of PTHrP and PTH to Treat Osteoporosis

University of Pittsburghn = 105May 2009 to Jun 2012

Osteoporosis

Trial pageClinicalTrials.govUpdated 24 Mar 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.